{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:53:38Z","timestamp":1785912818840,"version":"3.56.0"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.breast.2026.104831","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:51:47Z","timestamp":1780617107000},"page":"104831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice"],"prefix":"10.1016","volume":"88","author":[{"given":"Hope S.","family":"Rugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Cescon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Penault-Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanu","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafalda","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104831_bib1","series-title":"Algorithm for endocrine treatment and targeted therapy for HR-positive","year":"2023"},{"key":"10.1016\/j.breast.2026.104831_bib2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.24.00248","volume":"42","author":"Burstein","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib3","article-title":"Systemic treatment of patients with metastatic breast cancer: ASCO resource-stratified guideline","volume":"10","author":"Al Sukhun","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International Consensus Guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104831_bib5","series-title":"ESMO metastatic breast cancer living guideline: ER-Positive HER2-negative breast cancer v1.1 - may 2023","year":"2023"},{"key":"10.1016\/j.breast.2026.104831_bib6","series-title":"To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way","article-title":"\u00a9 National Comprehensive Cancer Network, Inc. 2026. All rights reserved","year":"2026"},{"key":"10.1016\/j.breast.2026.104831_bib7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.annonc.2024.04.012","article-title":"A phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results","volume":"35","author":"Hamilton","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib8","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1078-0432.CCR-23-1796","article-title":"Phase Ia\/b study of giredestrant \u00b1 palbociclib and \u00b1 luteinizing hormone-releasing hormone agonists in estrogen receptor-positive, HER2-negative, locally advanced\/metastatic breast cancer","volume":"30","author":"Jhaveri","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104831_bib10","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.2024.42.16_suppl.1015","article-title":"H3B-6545 in women with locally advanced\/metastatic estrogen receptor-positive (ER+), HER2 negative (\u2013) breast cancer (BC) (abstr)","volume":"42","author":"Hamilton","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib11","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","article-title":"VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2- advanced breast cancer","volume":"20","author":"Hamilton","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ygyno.2024.10.006","article-title":"Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent\/advanced ER-positive endometrioid endometrial cancer: results from the phase 1a\/1b EMBER study","volume":"191","author":"Yonemori","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib13","doi-asserted-by":"crossref","first-page":"TPS1135","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1135","article-title":"OPERA-01: a randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4\/6 inhibitors","volume":"42","author":"Pistilli","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib14","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.22.02807","article-title":"Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor-negative metastatic breast cancer: ASCO guideline rapid recommendation update","volume":"41","author":"Moy","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib15","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101931","volume":"59","author":"Lambertini","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.breast.2026.104831_bib17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.2023.41.16_suppl.1019","article-title":"Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4\/6 inhibitors: results from the AURORA molecular screening initiative","volume":"41","author":"Agostinetto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib18","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib19","volume":"1","year":"2026"},{"key":"10.1016\/j.breast.2026.104831_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102670","article-title":"Current and emerging treatment approaches for hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"123","author":"Jhaveri","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2026.104831_bib21","doi-asserted-by":"crossref","first-page":"PS17","DOI":"10.1158\/1538-7445.SABCS23-PS17-01","article-title":"Abstract PS17-01: key drivers of therapeutic response and resistance to giredestrant from GO39932: a phase Ia\/b study in patients with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer","volume":"84","author":"Liang","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2026.104831_bib22","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1200\/JCO.2023.41.16_suppl.1024","article-title":"Early prediction of endocrine responsiveness in ER+\/HER2 negative MBC: pilot study with 18F-fluoroestradiol (18F-FES) CT\/PET","volume":"41","author":"Gennari","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000527917","article-title":"CDK4\/6 inhibitors in advanced HR+\/HER2 - breast cancer: a multicenter real-world data analysis","volume":"18","author":"M\u00fcller","year":"2023","journal-title":"Breast Care"},{"key":"10.1016\/j.breast.2026.104831_bib24","doi-asserted-by":"crossref","first-page":"8821","DOI":"10.1002\/cam4.3491","article-title":"Optimal duration of prior endocrine therapy predicts the efficacy of fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer","volume":"9","author":"Zhao","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.breast.2026.104831_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41523-021-00222-y","article-title":"Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies","volume":"7","author":"Robertson","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.breast.2026.104831_bib26","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.24.00144","article-title":"Final results of RIGHT choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-Positive\/Human epidermal growth factor receptor 2-Negative advanced breast cancer","volume":"42","author":"Lu","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib27","unstructured":"Loibl S, Thill M, Rey J, Rautenberg B, Bjelic-Radisic V, Decker T, et al. Primary results of the randomised phase IV trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-\/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study. Presented at the San Antonio breast cancer symposium. San Antonio, TX, USA2024."},{"key":"10.1016\/j.breast.2026.104831_bib28","doi-asserted-by":"crossref","first-page":"S1215","DOI":"10.1016\/j.annonc.2024.08.2261","volume":"35","author":"de la Haba Rodriguez","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib29","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/1759-7714.15282","article-title":"Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4\/6 inhibitor in HR-positive\/HER2-negative metastatic breast cancer: a prospective study","volume":"15","author":"Wu","year":"2024","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.breast.2026.104831_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1413674","article-title":"Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4\/6 inhibitor and endocrine therapy: a meta-analysis","volume":"14","author":"Xia","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib31","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","article-title":"Elacestrant in ER+, HER2\u2212 metastatic breast cancer with ESR1-Mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and in clinical subgroups","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104831_bib79","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104831_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12885-023-11722-4","article-title":"The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on \u2265 1 line of endocrine therapy: systematic review and meta-analysis","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2026.104831_bib33","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1158\/1078-0432.CCR-20-0224","article-title":"ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor\u2013positive breast cancer: a combined analysis of the phase III SoFEA and EFECT trials","volume":"26","author":"Turner","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104831_bib78","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10549-019-05512-5","article-title":"Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer","volume":"180","author":"Shibayama","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104831_bib35","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.2023.41.16_suppl.1062","article-title":"Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2\u2013 mBC): prevalence, biomarker characteristics, and outcomes","volume":"41","author":"Jeselsohn","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib80","series-title":"Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer","author":"Cabel","year":"2025"},{"key":"10.1016\/j.breast.2026.104831_bib36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10549-024-07427-2","article-title":"Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(\u2212) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice","volume":"207","author":"Bhave","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104831_bib37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.breast.2022.01.014","article-title":"Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"62","author":"Lee","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104831_bib38","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor\u2013positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104831_bib39","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104831_bib75","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-21-3276","article-title":"Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant","volume":"28","author":"Tolaney","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104831_bib77","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-Mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104831_bib76","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with Inavolisib in PIK3CA-Mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104831_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101399","article-title":"210P Real-world outcomes in patients (pts) with HR+\/HER2\u2013 metastatic breast cancer (mBC) and germline\/tumour BRCA mutations (g\/tBRCA1\/2m) receiving 1st-line (1L) CDK4\/6i plus endocrine therapy (ET)","volume":"8","author":"Safonov","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104831_bib43","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/s41416-023-02248-4","article-title":"Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1\/2 mutation","volume":"128","author":"Frenel","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104831_bib44","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.annonc.2020.04.008","article-title":"Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients","volume":"31","author":"Ross","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib45","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1158\/0008-5472.CAN-12-4265","article-title":"GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors","volume":"73","author":"Morandi","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2026.104831_bib46","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10549-023-06937-9","article-title":"High expression of the RET receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer","volume":"199","author":"Kakati","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104831_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101389","article-title":"200P OlympiAD: exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)","volume":"8","author":"Robson","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104831_bib41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00018-019-03189-z","article-title":"Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients","volume":"77","author":"Keup","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.breast.2026.104831_bib47","first-page":"1","article-title":"A review of prognostic and predictive biomarkers in breast cancer","volume":"23","author":"Tarighati","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.breast.2026.104831_bib48","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40291-013-0077-9","article-title":"Prognostic and predictive biomarkers: tools in personalized oncology","volume":"18","author":"Nalejska","year":"2014","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.breast.2026.104831_bib49","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","article-title":"Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists guideline update","volume":"144","author":"Allison","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.breast.2026.104831_bib50","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","article-title":"Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer","volume":"17","author":"Harvey","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib51","doi-asserted-by":"crossref","first-page":"S312","DOI":"10.1016\/j.annonc.2024.08.181","article-title":"238MO PROMENADE: pembrolizumab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort","volume":"35","author":"Cherifi","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103831","article-title":"The \"lows\": update on ER-low and HER2-low breast cancer","volume":"78","author":"Fusco","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104831_bib53","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/annonc\/mdx397","article-title":"Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer","volume":"28","author":"Fujii","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib54","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2147\/OTT.S231493","article-title":"The prognostic impact of hormonal receptor and HER-2 expression discordance in metastatic breast cancer patients","volume":"13","author":"Yang","year":"2020","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.breast.2026.104831_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156222","article-title":"Estrogen receptor conversion in bone, liver and lung metastases from breast cancer","volume":"275","author":"Podany","year":"2025","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.breast.2026.104831_bib56","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1038\/s41379-020-0615-z","article-title":"Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution","volume":"33","author":"Chen","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.breast.2026.104831_bib57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41523-021-00252-6","article-title":"Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort","volume":"7","author":"Grinda","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.breast.2026.104831_bib58","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.breast.2014.08.009","article-title":"ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)","volume":"23","author":"Cardoso","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104831_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinsp.2024.100362","article-title":"Visceral crisis in metastatic breast cancer: an old concept with new perspectives","volume":"79","author":"Andrade","year":"2024","journal-title":"Clinics"},{"key":"10.1016\/j.breast.2026.104831_bib60","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib61","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/bmj.1.6071.1248","article-title":"Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer","volume":"1","author":"Priestman","year":"1977","journal-title":"Br Med J"},{"key":"10.1016\/j.breast.2026.104831_bib62","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.1986.4.2.186","article-title":"A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand breast cancer trials group, clinical oncological society of Australia","volume":"4","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib63","volume":"25","author":"Wilcken","year":"2003"},{"key":"10.1016\/j.breast.2026.104831_bib64","doi-asserted-by":"crossref","unstructured":"Dieras; V, Bidard; FC, Roca; L, Pierga; J, Bachelot; T, Desmoulins; I, et al. Primary results of ambre, a randomized phase 3comparing mono-chemotherapy (ct) vs abemaciclib + endocrine therapy (et) in hr+\/her2- advanced breast cancer (abc) with high visceral tumor burden [RF7-06]. SABCS. San Antonio, TX2025.","DOI":"10.1158\/1557-3265.SABCS25-RF7-06"},{"key":"10.1016\/j.breast.2026.104831_bib65","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.ejca.2013.04.011","article-title":"Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study","volume":"49","author":"Campone","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104831_bib66","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1001\/jamaoncol.2021.4301","article-title":"Fulvestrant-Palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor-positive, ERBB2-Negative advanced breast cancer: a randomized clinical trial","volume":"7","author":"Llombart-Cussac","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib67","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","article-title":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","volume":"27","author":"Xu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.breast.2026.104831_bib68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12916-023-03238-2","article-title":"A network meta-analysis of efficacy and safety for first-line and second\/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer","volume":"22","author":"Shao","year":"2024","journal-title":"BMC Med"},{"issue":"17","key":"10.1016\/j.breast.2026.104831_bib69","volume":"41","author":"Sonke","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib70","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1016\/j.annonc.2025.08.911","article-title":"487MO Overall survival with first versus second-line use of CDK4\/6 inhibitors in HR+\/HER2- advanced breast cancer","volume":"36","author":"Wortelboer","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib71","first-page":"645","volume":"34","author":"Tarantino","year":"2023"},{"key":"10.1016\/j.breast.2026.104831_bib72","author":"Metzger","year":"2024","journal-title":"SABCS"},{"key":"10.1016\/j.breast.2026.104831_bib73","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","article-title":"Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments","volume":"21","author":"Lone","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.breast.2026.104831_bib74","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib81","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055821","volume":"12","author":"Berger","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.breast.2026.104831_bib82","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1038\/s41598-023-31055-3","article-title":"Systematic review of NTRK 1\/2\/3 fusion prevalence pan-cancer and across solid tumours","volume":"13","author":"O'Haire","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2026.104831_bib83","article-title":"An integrative pan cancer analysis of RET aberrations and their potential clinical implications","volume":"12","author":"Zhou","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2026.104831_bib84","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104831_bib85","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1038\/s41467-018-07341-4","article-title":"RET rearrangements are actionable alterations in breast cancer","volume":"9","author":"Paratala","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.breast.2026.104831_bib86","first-page":"1136","article-title":"RET in breast cancer: pathogenic implications and mechanisms of drug resistance","volume":"2","author":"Lo Nigro","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.breast.2026.104831_bib87","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/emmm.201302625","article-title":"Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells","volume":"5","author":"Gattelli","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.breast.2026.104831_bib88","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.annonc.2023.08.011","article-title":"Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials","volume":"34","author":"Andr\u00e9","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib99","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.1016\/j.annonc.2023.09.590","article-title":"413P - characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2\u2013 aBC) who had rapid progression (RP) in acelERA BC","volume":"34","author":"Martin Jimenez","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib89","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jamaoncol.2020.5660","article-title":"Efficacy of circulating tumor cell count-driven vs clinician-driven first-line therapy choice in hormone receptor-positive, ERBB2-Negative metastatic breast cancer: the STIC CTC randomized clinical trial","volume":"7","author":"Bidard","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib90","doi-asserted-by":"crossref","first-page":"901","DOI":"10.21037\/atm-22-3797","article-title":"The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(-) metastatic breast cancer: a retrospective study","volume":"10","author":"Shao","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.breast.2026.104831_bib91","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1158\/1078-0432.CCR-21-1562","article-title":"Evaluating serum thymidine kinase 1 in patients with hormone receptor-positive metastatic breast cancer receiving first-line endocrine therapy in the SWOG S0226 trial","volume":"27","author":"Paoletti","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104831_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2023.03.001","article-title":"Serum thymidine kinase activity in patients with HR-positive\/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: results from the prospective BioItaLEE trial","volume":"186","author":"Malorni","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104831_bib93","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2019.04.002","article-title":"Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)","volume":"114","author":"McCartney","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104831_bib94","article-title":"Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)\/HER2-negative (HER2-) metastatic breast cancer patients","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib101","article-title":"Survival outcomes by TP53 mutation status in metastatic breast cancer","volume":"2018","author":"Meric-Bernstam","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib97","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial","volume":"8","author":"O'Leary","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.breast.2026.104831_bib98","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.1016\/j.annonc.2023.09.590","article-title":"413P - characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2\u2013 aBC) who had rapid progression (RP) in acelERA BC","volume":"34","author":"Martin Jimenez","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib95","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49373-w","article-title":"Aberrant regulation of RAD51 promotes resistance of neoadjuvant endocrine therapy in ER-positive breast cancer","volume":"9","author":"Jia","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2026.104831_bib96","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/ijc.25736","article-title":"High RAD51 mRNA expression characterize estrogen receptor-positive\/progesteron receptor-negative breast cancer and is associated with patient's outcome","volume":"129","author":"Barbano","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2026.104831_bib100","article-title":"Circulating tumor DNA predicts tumor recurrence in early-stage breast cancer: a meta-analysis","volume":"13","author":"Moat","year":"2026","journal-title":"Genes Dis"},{"key":"10.1016\/j.breast.2026.104831_bib102","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10549-018-5049-7","article-title":"Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations","volume":"174","author":"Jongen","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104831_bib103","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12967-018-1734-x","article-title":"Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients","volume":"17","author":"Liu","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.breast.2026.104831_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-026-10197-0","article-title":"Homologous recombination deficiency and hemizygosity drive resistance in breast cancer","author":"Safonov","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.breast.2026.104831_bib105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2967\/jnumed.107.047506","article-title":"Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol","volume":"49","author":"Peterson","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104831_bib106","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1158\/1078-0432.CCR-10-3321","article-title":"Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer","volume":"17","author":"Linden","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104831_bib107","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2025.43.16_suppl.1059","article-title":"Clinical utility of [18F]fluoroestradiol (FES) PET\/CT to guide second-line treatment decision in patients with ER-positive HER2-negative metastatic breast cancer progressing on first-line endocrine therapy","volume":"43","author":"Linden","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104831_bib108","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1158\/1078-0432.CCR-16-0362","article-title":"Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer","volume":"23","author":"Kurland","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104831_bib109","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41586-024-08167-5","article-title":"Automated real-world data integration improves cancer outcome prediction","volume":"636","author":"Jee","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.breast.2026.104831_bib110","volume":"43","author":"Razavi","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:36:32Z","timestamp":1785911792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":110,"alternative-id":["S0960977626001414"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104831","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104831"}}